Martek Pursues Cheaper DHA Cost Structure To Give Ingredient Wider Appeal
This article was originally published in The Tan Sheet
Executive Summary
Martek Biosciences is working toward substantially lowering the cost of making docosahexaenoic acid (DHA) through a business venture with a genetics seed company
You may also be interested in...
Martek/Abbott exclusive supply deal
Martek Biosciences will serve as exclusive worldwide supplier of DHA and ARA for Abbott Nutrition's infant formula products, including Similac Advance, under a new, long-term supply agreement announced Oct. 8. Abbott signed a 25-year, non-exclusive supply agreement with Martek in 2000 that will remain in effect (1"The Tan Sheet" Sept. 29, 2003, p. 14). The new deal provides for a 10-year term, though Abbott can terminate as of January 2012. Martek's life'sDHA and life'sARA ingredients are used in more than 95% of U.S. infant formulas...
Martek Stock To Raise $11 Mil. For Plant Upgrades; Firm Files Patent Suit
Martek Biosciences' recent stock sale under a shelf registration statement is expected to bring in $11.2 mil. and allow the firm further breathing room to continue expanding its major manufacturing facilities
Bristol Sells Its Mead Johnson Adult Nutritionals Business To Novartis
The divestiture of Mead Johnson's adult nutritionals business to Novartis Medical Nutrition will allow the Bristol-Myers Squibb division to concentrate on its infant formula franchise